Regulatory S16 Ep40: FDA Approval Insights: Zongertinib for HER2 TKD-Mutated NSCLC: With Julia Rotow, MD; and Martin Dietrich, MD, PhD OncLive PodcastIn today's episode, we spoke with Julia Rotow, MD, and Martin Dietrich, MD, PhD.RegulatoryOncologyRead full story pharminent March 30, 2026 (Last updated: March 31, 2026) OncLive Podcast In today’s episode, we spoke with Julia Rotow, MD, and Martin Dietrich, MD, PhD. RegulatoryOncologyRead full story Post navigation Previous: Blackstone closes $6.3B fund for life sciences investingNext: AZ considers filings for long-acting Strensiq follow-up Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026